Company Announcement: CytoMed Therapeutics Limited has entered into an At-the-Market Sales Agreement with R.F. Lafferty & Co., Inc. to sell ordinary shares valued up to $4,304,945.
Use of Proceeds: The funds raised will be used for general corporate purposes, including business diversification, development initiatives, and potential acquisitions or strategic investments.
Recent Developments: Since acquiring a cord blood bank in August 2024, CytoMed has gained approximately 2,500 new customer sign-ups, contributing to its revenue in 2025.
Forward-Looking Statements: The press release includes forward-looking statements about the company's plans and performance, which are subject to risks and uncertainties that may affect actual results.
GDTC
$1.62+Infinity%1D
Analyst Views on GDTC
About GDTC
CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The Company also has the allogeneic gamma delta T cell technology, namely TCB-002.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
